NDA 020864 · Organon LLC
Maxalt
Rizatriptan Benzoate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Oct 1, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Jun 29, 1998
Approved uses
5
Original approval plus efficacy supplements
Registered trials
14
11 Phase 3, 1 recruiting
FAERS reports
9,569
5,593 serious, 175 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 29, 2026.
MAXALT ® and MAXALT-MLT ® are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use MAXALT should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with MAXALT, the diagnosis of migraine should be reconsidered before MAXALT is administered to treat any subsequent attacks. MAXALT is not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4) ] . MAXALT is not indicated for the prevention of migraine attacks. Safety and effectiveness of MAXALT have not been established for cluster headache. MAXALT is a serotonin (5-HT) 1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years of age ( 1 ) Limitations of Use : Use only after clear diagnosis of migraine has been established ( 1 ) Not indicated for the prophylactic therapy of migraine ( 1 ) Not indicated for the treatment of cluster headache ( 1 )
Mechanism: Rizatriptan binds with high affinity to human cloned 5-HT 1B/1D receptors. MAXALT presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT 1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 16, 2011 Supplement 18 · Efficacy · priority review LabelLetter
- Dec 11, 2000 Supplement 5 · Efficacy Review
- Jun 21, 2000 Supplement 2 · Efficacy Review
- Nov 16, 1999 Supplement 3 · Efficacy Letter
- Jun 29, 1998 Original approval · Type 1 - New Molecular Entity LetterReviewOther Important Information from FDA
2 products under this application
- MAXALT · RIZATRIPTAN BENZOATE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
- MAXALT · RIZATRIPTAN BENZOATE EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Rizatriptan Benzoate" as an intervention, any sponsor and status, largest first.
- MK0462 in Treatment of Migraine With Recurrence (MK0462-022)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00897949 · 1,473 participants · Start Mar 1995 · Primary completion Jan 1996
Drug: rizatriptan benzoate (MK0462); Comparator: placebo · For: Migraine Headache
- Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00898677 · 1,268 participants · Start Sep 1995 · Primary completion May 1996
Drug: rizatriptan benzoate; rizatriptan benzoate and 2 more · For: Migraine Headache
- MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00897104 · 933 participants · Start Aug 1995 · Primary completion May 1996
Drug: rizatriptan benzoate (MK0462); Comparator: sumatriptan and 1 more · For: Migraine Headache
- A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01004263 · 674 participants · Start Dec 1, 2009 · Primary completion Apr 18, 2011
Drug: rizatriptan benzoate · For: Acute Migraine With or Without Aura in Adolescents
- Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00092963 · 529 participants · Start Aug 17, 2004 · Primary completion Jan 14, 2005
Drug: MK0462, rizatriptan benzoate / Duration of Treatment: 1day; Comparator: placebo / Duration of Treatment: 1 day · For: Migraine
- Treatment of Multiple Attacks of Acute Migraine (0462-025)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00899379 · 473 participants · Start Apr 1995 · Primary completion Jan 1996
Drug: rizatriptan benzoate; Comparator: Placebo · For: Migraine Headache
- Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00111709 · 393 participants · Start May 27, 2005 · Primary completion Feb 24, 2006
Drug: MK0462, rizatriptan benzoate / Duration of Treatment -1 day; Comparator: placebo / Duration of Treatment - 1 day · For: Migraine
- Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00111722 · 393 participants · Start May 27, 2005 · Primary completion Feb 15, 2006
Drug: MK0462, rizatriptan benzoate / Duration of Treatment -1day; Comparator: placebo / Duration of Treatment - 1 day · For: Migraine
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,547
- nausea1,200
- headache1,016
- off label use953
- migraine934
- product use in unapproved indication642
- fatigue609
- hyperhidrosis591
- pain568
- sedation498
- nightmare497
- nephrolithiasis457
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 97 |
| 2005 | 101 |
| 2006 | 110 |
| 2007 | 119 |
| 2008 | 136 |
| 2009 | 169 |
| 2010 | 224 |
| 2011 | 301 |
| 2012 | 406 |
| 2013 | 349 |
| 2014 | 371 |
| 2015 | 537 |
| 2016 | 835 |
| 2017 | 487 |
| 2018 | 608 |
| 2019 | 767 |
| 2020 | 682 |
| 2021 | 594 |
| 2022 | 601 |
| 2023 | 512 |
| 2024 | 545 |
| 2025 | 526 |
| 2026 | 492 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Maxalt (Rizatriptan Benzoate)
2024 spending
$1.1M
Beneficiaries
317
1,427 claims
Per beneficiary
$3,620
$40.70 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $159,447 |
| 2022 | $1,197,588 |
| 2023 | $1,329,530 |
| 2024 | $1,147,397 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Rizatriptan for acute migraine.
Oldman AD, Smith LA, McQuay HJ, et al. · Cochrane Database Syst Rev 2001 · Systematic Review
- WITHDRAWN: Rizatriptan for acute migraine.
Oldman AD, Smith LA, McQuay HJ, et al. · Cochrane Database Syst Rev 2007 · Systematic Review
- [Comparative clinical study of pharmacokinetics and bioequivalence of Relonova and Maxalt].
Khokhlov AL, Leykin ZN · Zh Nevrol Psikhiatr Im S S Korsakova 2023 · English Abstract, Equivalence Trial
- Migraine therapeutics in adolescents: a systematic analysis and historic perspectives of triptan trials in adolescents.
Sun H, Bastings E, Temeck J, et al. · JAMA Pediatr 2013 · Meta-Analysis, Systematic Review
- Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine.
Bomhof M, Paz J, Legg N, et al. · Eur Neurol 1999 · Clinical Trial, Comparative Study
- Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy.
Kelman L, Von Seggern RL · Am J Ther 2006 · Comparative Study, Meta-Analysis
Sponsor: Organon LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.